(외신단독제보)[진원생명과학011000] 이노비오 hpv효과 입증
이노비오의 HPV(인유두종 바이러스)유발 암 치료 DNA백신, 두경부암 환자의 종양조직과 말초혈액에서 T세포 면역반응 생성.
INO-3112 관련 예전기사)
[특징주]진원생명과학, 관계사 7.3억弗 수출계약에 上
http://www.mt.co.kr/view/mtview.php?type=1&no=2015081109111262078&outlink=1
진원생명과학은 이날 관계회사 이노비오가 다국적제약사 아스트라제네카의 바이오의약품 연구개발 전문 자회사인 메드이뮨과 HPV 유발 암 치료 DNA백신 후보물질 'INO-3112'에 대한 총 7억3000만달러 규모의 기술수출(라이선스 아웃) 계약을 체결했다고 밝혔다.
Inovio’s Cancer Immunotherapy (INO-3112) Generates T Cell Immune Responses in Tumor Tissue and Peripheral Blood in Patients with HPV-Associated Head and Neck Cancer
Four of five study subjects in treated group show progression free survival ranging from nine to 24 months to date in phase I/IIa clinical study
PLYMOUTH MEETING, Pa., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO), today announced an interim data analysis showing that its INO-3112 cancer immunotherapy product generated antigen-specific CD8+ killer T cell responses measured both in tumor tissue and in peripheral blood from subjects with head and neck cancer associated with human papillomavirus (HPV). The immunology results show that INO-3112 treatment generated robust HPV16/18 specific CD8+ T cell responses in peripheral blood in four of five subjects who also showed increased T cell activation in resected tumor tissue samples. These four subjects remained disease free in continuing follow-up that ranged from nine to 24 months at the time of analysis. One subject with only minimal increases in T cell immune responses developed progressive disease at 11 months post start of the study. These results were presented November 12th at the 2016 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in National Harbor, Maryland.
http://ir.inovio.com/news/news-releases/news-releases-details/2016/Inovios-Cancer-Immunotherapy-INO-3112-Generates-T-Cell-Immune-Responses-in-Tumor-Tissue-and-Peripheral-Blood-in-Patients-with-HPV-Associated-Head-and-Neck-Cancer/default.aspx
- 국내 최고 빠른 증시 속보/루머 전문/ 전국 유.무료 통합1위 -
- 제보는 언제든 환영합니다 -
본 내용은 개인적 사견으로 오류 허위 지연이 있을수 있으므로 절대 매매 판단의 자료가 될 수 없으며 이로인해 일어나는 모든 책임은 본인에게 있음을 알려드립니다. 따라서 원치 않으실 경우 수신 거부 하여 주시기 바랍니다.